Plant Name: Atalantia racemosa
Taxonomic Information:
Plant ID: NPO1834
Plant Latin Name: Atalantia racemosa
Taxonomy Genus: Atalantia
Taxonomy Family: Rutaceae
Plant External Links:
NCBI TaxonomyDB:
159026
Plant-of-the-World-Online:
771423-1
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
TCM; SiddhaGeographical Distribution:
Myanmar; Philippines; India; Vietnam; China; Sri Lanka
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| ALPL; ALOX12; HSD17B2; HSD17B10; NOX4; POLB; | |
| ACHE; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA14; CA7; CA4; | |
| ESR1; | |
| NR1H4; | |
| TYR; | |
| KDM4E; | |
| AHR; NFKB1; | |
| FUT7; | |
| SLC5A1; SLC5A2; SLC5A4; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| SLC superfamily of solute carriers | SLC5A1 | Sodium/glucose cotransporter 1 | P13866 | CHEMBL4979 |
| SLC superfamily of solute carriers | SLC5A2 | Sodium/glucose cotransporter 2 | P31639 | CHEMBL3884 |
| SLC superfamily of solute carriers | SLC5A4 | Low affinity sodium-glucose cotransporter | Q9NY91 | CHEMBL1770047 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.988E-11 | 1.086E-06 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.735E-08 | 6.297E-05 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005215; transporter activity | GO:0005412; glucose:sodium symporter activity | 1.184E-07 | 1.719E-04 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.735E-07 | 5.677E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.070E-07 | 6.694E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.433E-06 | 1.007E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.490E-06 | 1.595E-03 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, LMNA, NFKB1, NR1H4, PIM1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.268E-06 | 1.924E-03 | ALPL, CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.811E-06 | 2.943E-03 | CYP1A1, CYP1A2, CYP1B1, ESR1, HSD17B2, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.727E-06 | 3.469E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:0035428; hexose transmembrane transport | 8.935E-06 | 3.538E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0051179; localization | GO:1904659; glucose transmembrane transport | 8.935E-06 | 3.538E-03 | SLC5A1, SLC5A2, SLC5A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.012E-05 | 3.853E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.026E-05 | 3.853E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.026E-05 | 3.853E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.118E-05 | 4.126E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 1.959E-05 | 6.426E-03 | AXL, CA2, CDK1, CYP1A1, CYP1A2, CYP1B1, KDR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.022E-05 | 6.426E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 2.321E-05 | 6.924E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.950E-05 | 8.225E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.984E-05 | 8.225E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.618E-11 | 1.026E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.919E-06 | 1.142E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.499E-06 | 1.388E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.055E-05 | 1.504E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.466E-04 | 3.489E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.706E-04 | 5.600E-03 | KDR, ESR1, MET, IGF1R |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.814E-04 | 4.544E-03 | CA2, NR1H4, SLC5A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.985E-04 | 4.544E-03 | FLT3, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.055E-04 | 4.544E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.159E-04 | 7.718E-03 | KDR, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.302E-04 | 5.600E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 7.783E-04 | 7.718E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; SLC5A4; SLC5A1; SLC5A2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | SLC5A4; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | SLC5A2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; SLC5A2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SLC5A4; SLC5A1; SLC5A2; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
